Who invested in AlloVir

One round we have observed, with the 10 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$120Mraised across 1 round since 2019, from 1 source

Latest round: Series B, $120MMay 2019
Led by: UBS Oncology Impact Fund
Investors: 10 (1 led)

See who backed them

The rounds

May 2019
Series B$120M
- UBS Oncology Impact FundLead
- Fidelity
- Invus
- Redmile Group
- Samsara BioCapital
- EcoR1 Capital
- Leerink Partners
- F2
- Research Company
- particpation from Gilead Sciences
Reported by Crunchbase NewsSEC filing: $121M sold, first sale May 2019

Founders and team

From AlloVir's own website and the SEC filings it signed: 5 on the team.

Andrew OxtobyCEO & Director
Liisa BaykoCFO
Nancy DavisVP Clinical Operations
David HallalBoard Chairman
Vikas SinhaExecutive Officer, Directori

On the board, as filediAnsbert GadickeJohn WilsonJuan VeraMalcom BrennerMorana Jovan-Embiricos

Everyone who backed them

UBS Oncology Impact FundVC firm1round, led 1

FidelityVC firm1round

InvusPrivate equity1round

Redmile GroupVC firm1round

Samsara BioCapitalVC firm1round

EcoR1 CapitalPrivate equity1round

Leerink PartnersGrowth equity1round

F2VC firm1round

Research CompanyInvestment firm1round

particpation from Gilead Sciencesno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about AlloVir

Who invested in AlloVir?

AlloVir's investors include UBS Oncology Impact Fund, Fidelity, Invus, Redmile Group and Samsara BioCapital, and 5 more on record. UBS Oncology Impact Fund led its latest round.